Drug Prices
The U.S. health care system is facing a prescription drug spending crisis fueled by staggering increases in recent years in the price of drugs.
National health expenditures are projected to grow an average 5.5% annually during 2017-2026, outpacing average projected growth in gross domestic product by 1 percentage point, the Centers for Medicare & Medicaid Services’ Office of the Actuary reported yesterday.
The House Ways and Means Committee today held a hearing on the Department of Health and Human Services’ fiscal year 2019 budget request, at which HHS Secretary Alex Azar testified.
More than 40 organizations, including the AHA, today urged House and Senate leaders to swiftly pass the Creating and Restoring Equal Access to Equivalent Samples Act (S. 974/H.R. 2212).
A bipartisan group of 30 senators and 64 representatives Friday asked Food and Drug Administration Commissioner Scott Gottlieb, M.D., to take all available action to address current intravenous saline shortages affecting hospitals across the country.
In his state of the union address last night, President Trump said reducing prescription drug prices is “one of my greatest priorities.”
While there has been recent high profile media coverage of retail drug price increases, the hospital inpatient pharmaceutical market is often overlooked and is not systematically evaluated. This report presents recent trends in hospital inpatient drug prices and spending, providing policymakers and…
Prescription drug prices are out of control. The average annual cost for one specialty medication to treat a chronic condition is now more than what most families earn in a year. Big Pharma could solve the problem by committing to more rational and sustainable pricing models.
The House Energy and Commerce Committee yesterday released a report on the 340B Drug Pricing Program. “The 340B program is an important program that enjoys strong bipartisan support in Congress,” the report says.
The Senate Finance Committee today held a hearing for Alex Azar, President Trump’s nominee for secretary of Health and Human Services. Azar, former president of Lilly USA and deputy HHS secretary under the George W. Bush administration, faced a number of questions from senators about his ties to…